Skip to content

Author

Mustafa Saleh

We have 7 of 22 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

49 Effect of Co-Morbidity Burden on the Efficacy and Tolerability of Belzutifan in Patients with Metastatic Renal Cell Carcinoma

Abstract Background Belzutifan, a hypoxia-inducible factor-2α (HIF-2α) inhibitor, has demonstrated efficacy in advanced clear-cell renal cell carcinoma (ccRCC) in patients previously received immunotherapy (IO) and anti-angiogenics. However, comorbidities pose a challenge in cancer management and often limit inclusion...

Ali Hajj Ali, Liliana Ascione, R. Nawfal et al. · 0 citations
Open access Sep 2026

72 Time-of-day of Immune Checkpoint Inhibitor Infusion and Overall Survival in Renal Cell Carcinoma: A Real-World Cohort Analysis

Abstract Background Previous retrospective work found an association between earlier immune-checkpoint inhibitors (ICI) infusion times and survival outcomes in renal cell carcinoma (RCC). A recent randomized trial in non-small cell lung cancer (NSCLC) also reported benefit, however, a recent analysis of several randomi...

P. Barrios, Mustafa Saleh, Liliana Ascione et al. · 0 citations
Open access Sep 2026

70 Lymphocyte Hsp70 is a Novel Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma

A scRNA-seq atlas of tumors from metastatic RCC found a novel factor, Hsp70, that in lymphocytes strongly predicts response and greatly extended PFS after ICI, indicating that Hsp70 expression in lymphocytes predicts response to ICI across timepoints and cohorts.

Ethan C. Burns, S. Kashima, Rishabh Rout et al. · 0 citations
Open access Sep 2026

54 Primary Progressive Disease and Outcomes with First-Line Nivolumab Plus Ipilimumab in Metastatic Renal Cell Carcinoma: A Real-World IMDC Analysis

Abstract Background Nivolumab plus ipilimumab (NIVO+IPI) combination therapy is a first-line standard in metastatic renal cell carcinoma (mRCC). Despite durable responses in some patients, over 20% develop primary progressive disease (PPD) at first restaging imaging. In this study, we evaluated clinical factors associa...

É. Ibrahim, Wan-Ling Xie, R. El Hajj Chehade et al. · 0 citations
Open access Sep 2026

75 Transcriptional Correlates of ARNT Expression and its Impact on Survival Outcomes in Clear-Cell Renal Cell Carcinoma (ccRCC)

Across three cohorts, higher ARNT expression correlated with higher BHS, and a consistent correlation was observed between ARNT and EPAS1 and HIF1A expressions, and a consistent correlation was observed between ARNT and EPAS1 expressions.

Wassim Daoud Khatoun, Ali Hajj Ali, Eddy Saad et al. · 0 citations
Open access Sep 2026

8 Single Cell Transcriptomic Investigation of Renal Cell Carcinoma (RCC) Reveals Tissue Resident Memory Exhausted CD8+ T Cell Signature Associated with Resistance to Immune Checkpoint Inhibition (ICI)

A tissue residency gene program in Tex cells associated with non-response to immunotherapy was identified and nominates resident memory exhausted CD8+ T cells as a targetable subset of cells to improve CD8+ T cell-mediated anti-tumor immunity.

Rishabh Rout, S. Kashima, M. Hugaboom et al. · 0 citations
Open access Sep 2026

51 Discovery of Exhausted CD8+ T-cell States Associated with Clinical Outcomes in Renal Cell Carcinoma

It is found that baseline tumor infiltration by exhausted T cells with a resident memory phenotype (Tex-rm) is significantly associated with worse PFS in advanced RCC patients receiving ICI monotherapy or ICI+TKI combination therapy.

Zhao-Chen Ye, S. Kashima, Rishabh Rout et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.